COVID-19 Vaccine Safety Now: Soft Rollout, Not Pause, After Reports Of Guillain-Barré Syndrome

 
• By Brenda Sandburg

Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.

J&J vaccine
CDC and FDA report rare cases of neurological disorder with J&J's COVID-19 vaccine • Source: Alamy

More from Vaccines

More from Pink Sheet